Dr. Reddy’s Laboratories is currently trading at Rs. 5551.05, up by 74.55 points or 1.36% from its previous closing of Rs. 5476.50 on the BSE. The scrip opened at Rs. 5535.00 and has touched a high and low of Rs. 5613.85 and Rs. 5425.00 respectively. So far 36005 shares were traded on the counter. The … Read more
Dr. Reddy’s Laboratories’ wholly owned subsidiary — Aurigene Discovery Technologies (Aurigene) and Olema Pharmaceuticals, Inc (Olema) have entered into exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target. Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights … Read more
Dr. Reddy’s Laboratories has launched B2B customer service portal ‘XCEED’ to increase the operational efficiency. The portal is focused on meeting the growing demand for the company’s portfolio of generic active pharmaceutical ingredients (APIs). The platform will be presented for the first time to customers during DCAT week in New York from March 18 to … Read more